NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note published on Tuesday morning,Benzinga reports. The firm currently has a $40.00 price objective on the stock.

Several other brokerages have also recently weighed in on NRXP. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, December 2nd. Zacks Research raised shares of NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. BTIG Research restated a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ NRXP opened at $2.18 on Tuesday. NRx Pharmaceuticals has a 1 year low of $1.40 and a 1 year high of $6.01. The stock has a market capitalization of $64.53 million, a P/E ratio of -0.93 and a beta of 1.91. The company’s 50-day moving average is $2.60 and its 200 day moving average is $2.86.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $6.83 million. Research analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of institutional investors have recently made changes to their positions in NRXP. Ethos Financial Group LLC purchased a new position in NRx Pharmaceuticals in the 3rd quarter worth approximately $39,000. One Wealth Management Investment & Advisory Services LLC increased its holdings in shares of NRx Pharmaceuticals by 86.1% in the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. Finally, AdvisorShares Investments LLC boosted its position in shares of NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.